About Provasculon
Provasculon is a company based in Cambridge (United States) founded in 2007 was acquired by Mesoblast in June 2013. Provasculon has raised $6 million across 1 funding round from investors including Biogen, Mesoblast and Partners HealthCare. Provasculon operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Provasculon
Unlock access to complete
Unlock access to complete
Funding Insights of Provasculon
Provasculon has successfully raised a total of $6M through 1 strategic funding round. The most recent funding activity was a Series A round of $6 million completed in March 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Provasculon
Provasculon has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Biogen, Mesoblast and Partners HealthCare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Therapies for neurodegenerative and immunology disorders are developed.
|
Locked | Locked | Locked | |
|
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
Locked | Locked | Locked |
Investor details for Provasculon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Provasculon
Investment portfolio details for Provasculon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Provasculon
Detailed financials for Provasculon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Provasculon Comparisons
Peer comparison for Provasculon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Provasculon
Provasculon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Detailed competitors of Provasculon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Provasculon
Complete news archive for Provasculon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Provasculon
Provasculon was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Provasculon is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Provasculon is a funded company, having raised a total of $6M across 1 funding round to date.
Founded in 2007 in Cambridge, United States, Provasculon is focused on regenerative medicine within the life sciences sector. Genetically engineered versions of the SDF-1 protein are developed to attract endothelial progenitor stem cells to damaged heart tissue, supporting new blood vessel formation post-heart attacks. Since 2013, operations have been maintained as a subsidiary of Mesoblast Limited.
Provasculon's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.